当着夫的面被夫上司玩弄,最近免费中文字幕中文高清百度 ,超碰CAOPORON入口,精品国产日韩一区二区三区

上海莼試生物技術(shù)有限公司

主營(yíng)產(chǎn)品: ELISA試劑盒,ELISA試劑盒價(jià)格,ELISA試劑盒報(bào)價(jià)

8

聯(lián)系電話

13585831301

您現(xiàn)在的位置: 上海莼試生物技術(shù)有限公司>>生化試劑>>其它生化試劑>> 三氧化鉬1313-27-5說(shuō)明書(shū)

公司信息

聯(lián)人:
李小姐
話:
021-59541103
機(jī):
13585831301
售后電話:
13585831301
真:
021-60443211
址:
上海市嘉定區(qū)嘉羅公路1661號(hào)
編:
網(wǎng)址:
鋪:
http://www.yixinui.com/st562820/
給他留言
三氧化鉬1313-27-5說(shuō)明書(shū)
三氧化鉬1313-27-5說(shuō)明書(shū)
參考價(jià) 面議
具體成交價(jià)以合同協(xié)議為準(zhǔn)
  • 型號(hào)
  • 品牌
  • 廠商性質(zhì) 經(jīng)銷(xiāo)商
  • 所在地 上海市

更新時(shí)間:2021-12-28 17:07:42瀏覽次數(shù):387

聯(lián)系我們時(shí)請(qǐng)說(shuō)明是環(huán)保在線上看到的信息,謝謝!

【簡(jiǎn)單介紹】
三氧化鉬1313-27-5說(shuō)明書(shū)避光、干燥陰涼處封閉貯存,嚴(yán)禁與有毒、有害物品混放、混運(yùn)。本品為非危險(xiǎn) 產(chǎn)品可按一般化學(xué)品運(yùn)輸,輕搬動(dòng)輕放,防止日曬、雨淋!受熱、受潮、受光后易喪失活力,保存期短,因此貯存和運(yùn)輸條件比較苛刻。?

三氧化鉬1313-27-5說(shuō)明書(shū)儲(chǔ)存條件: 避光、干燥陰涼處封閉貯存,嚴(yán)禁與有毒、有害物品混放、混運(yùn)。本品為非危險(xiǎn) 產(chǎn)品可按一般化學(xué)品運(yùn)輸,輕搬動(dòng)輕放,防止日曬、雨淋!受熱、受潮、受光后易喪失活力,保存期短,因此貯存和運(yùn)輸條件比較苛刻。

產(chǎn)品名稱(chēng)英文名稱(chēng)價(jià)格

 三氧化鉬1313-27-5說(shuō)明書(shū)

  Molybdic anhydride

 1313-27-5電詢(xún)
 

其他中文名稱(chēng): 氧化鉬(VI);鉬酐;無(wú)水鉬酸;鉬酸酐;氧化鉬 
英文名稱(chēng): Molybdic anhydride 
其他英文名稱(chēng): Molybdenum(VI) oxide; Molybdic acid anhydride 
產(chǎn)品規(guī)格: 4N 
包裝:100克 
產(chǎn)品規(guī)格: AR 
包裝:100克/500克
:1313-27-5
MoO3=143.94
級(jí)別:4N
級(jí)別:AR
氯化物:≤0.005%
氨水不溶物:≤0.01%
重金屬:≤0.005%
性狀:、淺黃色或微帶藍(lán)色的粉末或粒狀。在795℃熔融成深黃色液體,凝結(jié)時(shí)成黃結(jié)晶。在較高溫度升華。在28℃時(shí)1L水可溶解0.49g。溶于濃礦酸、氫氧化堿溶液、氨水和酒石酸氫鉀的溶液,強(qiáng)烈灼燒后極微溶于酸類(lèi)。相對(duì)密度(d264)4.696。熔點(diǎn)795℃。沸點(diǎn)1155℃。中等毒,半數(shù)致死量(大鼠,經(jīng)口)125mg/kg。有刺激性。
用途:生化研究。比色法測(cè)定血糖、蛋白質(zhì)、酚、砷、鉛、鉍等。生物堿檢驗(yàn)。石油工業(yè)催化劑。鉬鹽、鉬合金的。五氧化二磷、雙氧水、酚和醇類(lèi)的還原劑
保存:RT

特點(diǎn):

1,全:公司提供上萬(wàn)種產(chǎn)品,涵蓋了生物試劑,elisa試劑盒,標(biāo)準(zhǔn)品,培養(yǎng)基,原裝耗材等,基本上各種科研所需產(chǎn)品在我司都能找到。 
2,新:產(chǎn)品更新速度較快,基本上每周都有新產(chǎn)品出現(xiàn)。
3,優(yōu):產(chǎn)品質(zhì)量好,*。
4,品牌多:公司代理sigma,amresco,oxoid,wako,R&D,RB,MBL,TCI,GIBIO,等國(guó)內(nèi)外 
5.售后:我公司具有優(yōu)質(zhì)的技術(shù)團(tuán)隊(duì),產(chǎn)品一旦售出,實(shí)驗(yàn)過(guò)程中遇到困難可提供在線技術(shù)咨詢(xún)。使您使用產(chǎn)品時(shí)沒(méi)有任何的后顧之憂(yōu)。 
要優(yōu)級(jí)純、分級(jí)純和化學(xué)純3種:
(1)優(yōu)級(jí)純(GR:Guaranteed reagent),又稱(chēng)一級(jí)品或保證試劑,99.8%,這種試劑純度zui高,雜質(zhì)含量zui低,適合于重要精密的分析工作和科學(xué)研究工作,使用綠色瓶簽。 
(2)分析純(AR),又稱(chēng)二級(jí)試劑,純度很高,99.7%,略次于優(yōu)級(jí)純,適合于重要分析及一般研究工作,使用紅色瓶簽。 
(3)化學(xué)純(CP),又稱(chēng)三級(jí)試劑,≥ 99.5%,純度與分析純相差較大,適用于工礦、學(xué)校一般分析工作。使用藍(lán)色(深藍(lán)色)標(biāo)簽。 
(4)實(shí)驗(yàn)試劑(LR:Laboratory reagent),又稱(chēng)四級(jí)試劑。
公司提供的*,貨源充足。嚴(yán)格的質(zhì)量控制體系,包括:優(yōu)級(jí)純,分析純,化學(xué)純,,試劑級(jí),基準(zhǔn)試劑,實(shí)驗(yàn)純,教學(xué)試劑,高純?cè)噭?,色譜純,光譜純,電子純。各種包裝規(guī)格,并可提供包裝定制,咨詢(xún)訂購(gòu)。
咪唑(100045
*(BH-7 7
錳079815
鎂合金分析用標(biāo)準(zhǔn)溶液(GSB04-2815-2011
鎂Mg(GSBG62005-90
鎂07982 
*(100428
美侖(100059
霉酚酸(5857
煤物理性質(zhì)和化學(xué)成分分析標(biāo)準(zhǔn)物質(zhì)(G11105f
煤物理性質(zhì)和化學(xué)成分分析標(biāo)準(zhǔn)物質(zhì)(G1110 h
煤物理化學(xué)成分分析標(biāo)準(zhǔn)物質(zhì)(煙煤5#(GSB06-2110-2007(ZBM106
沒(méi)食子酸丙酯成分分析標(biāo)準(zhǔn)物質(zhì)(40  
沒(méi)食子兒茶素沒(méi)食子酸酯(5964
沒(méi)食子兒茶素(棓兒茶酸、沒(méi)食子酰兒茶素(5542
毛喉素(5820
毛喉素(5819
毛地黃毒苷(5916
芒果苷(5058
*(5898
*(171201
(5050

2-Bromo-N-[3-[(1-oxobutyl)amino]phenyl]benzamide
2-Bromo-N-[3-[(1-oxobutyl)amino]phenyl]benzamide
2-[Methyl(tetrahydro-1,1-dioxido-3-thienyl)amino]-2-oxoethyl (E)-3-(3-nitrophenyl)prop-2-enoate
2-[Methyl(tetrahydro-1,1-dioxido-3-thienyl)amino]-2-oxoethyl (E)-3-(3-nitrophenyl)prop-2-enoate
(E)-
3-(2-Imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-[4-[(4-methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)phenyl]-benzamide; AP24534
(E)-
(E)-
(E)-
N-[2-Methyl-4-[2-(2-methylphenyl)diazenyl]phenyl]-2-furancarboxamide
N-[2-Methyl-4-[2-(2-methylphenyl)diazenyl]phenyl]-2-furancarboxamide
2-[(2-Methoxyethyl)thio]-3-methyl-1,4-naphthalenedione; VK3-OMe
2-[(2-Methoxyethyl)thio]-3-methyl-1,4-naphthalenedione; VK3-OMe
trans-4-[8-Ami-(7-chloro-1H-indol-2-yl)imidazo[1,5-a]pyrazin-3-yl]-cyclohexanecarboxylic acid
trans-4-[8-Ami-(7-chloro-1H-indol-2-yl)imidazo[1,5-a]pyrazin-3-yl]-cyclohexanecarboxylic acid
N’-[(Z)-pyrrol-2-ylidenemethyl]-2-(2,4,6-trichlorophenoxy)acetohydrazide; (2,4,6-Trichlorophenoxy)-acetic acid (1H-pyrrol-2-ylmethylene)-hydrazide; CID-49843203
N’-[(Z)-pyrrol-2-ylidenemethyl]-2-(2,4,6-trichlorophenoxy)acetohydrazide; (2,4,6-Trichlorophenoxy)-acetic acid (1H-pyrrol-2-ylmethylene)-hydrazide; CID-49843203
N-Benzyl-2-(2,3-dihydro-1,4-benzoxazin-4-yl)-5,6,7,8-tetrahydroquinazolin-4-amine;CID49830260
N-Benzyl-2-(2,3-dihydro-1,4-benzoxazin-4-yl)-5,6,7,8-tetrahydroquinazolin-4-amine;CID49830260
LY-404187; N-[2-(4’-cyanobiphenyl-4-yl)propyl]propane-2-sulfonamide
LY-404187; N-[2-(4’-cyanobiphenyl-4-yl)propyl]propane-2-sulfonamide
(T-4)-[(1E,6E)-1,7-Bis[4-(dimethylamino)phenyl]-1,6-heptadiene-3,5-dionato-kO3,kO5]difluoroboron
(T-4)-[(1E,6E)-1,7-Bis[4-(dimethylamino)phenyl]-1,6-heptadiene-3,5-dionato-kO3,kO5]difluoroboron
2-[[5-[5-(4-hydroxyphenyl)thiophen-2-yl]thiophen-2-yl]methylidene]propanedinitrile
2-[[5-[5-(4-hydroxyphenyl)thiophen-2-yl]thiophen-2-yl]methylidene]propanedinitrile
N-(6-(4-(2-((4-methylpiperazin-1yl)methyl)-3-(trifluoromethyl)phenyl)amino)-2-oxoethyl)phenoxy)pyrimidin-4-yl)cyclopropanecarboxamide
N-(6-(4-(2-((4-methylpiperazin-1yl)methyl)-3-(trifluoromethyl)phenyl)amino)-2-oxoethyl)phenoxy)pyrimidin-4-yl)cyclopropanecarboxamide
[1aS-(1aα,8β,8aα,8bα)]-6-Amino-8-[[(aminocarbonyl)oxy]methyl]-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methylazirino[2’,3’:3,4]pyrrolo[1,2-a]indole-4,7-dione; Ametycine
[1aS-(1aα,8β,8aα,8bα)]-6-Amino-8-[[(aminocarbonyl)oxy]methyl]-1,1a,2,8,8a,8b-hexahydro-8a-methoxy-5-methylazirino[2’,3’:3,4]pyrrolo[1,2-a]indole-4,7-dione; Ametycine
N’-(5-chloropyridin-2-yl)-N-[(1S,2R,4S)-4-(dimethylcarbamoyl)-2-[(5-methyl-6,7-dihydro-4H-[1,3]thiazolo[5,4-c]pyridine-2-carbonyl)amino]cyclohexyl]oxamide; DU 176b; DU-176; DU-176b; DU176b
N’-(5-chloropyridin-2-yl)-N-[(1S,2R,4S)-4-(dimethylcarbamoyl)-2-[(5-methyl-6,7-dihydro-4H-[1,3]thiazolo[5,4-c]pyridine-2-carbonyl)amino]cyclohexyl]oxamide; DU 176b; DU-176; DU-176b; DU176b
(2S)-isopropyl 2-(((((2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate; Sofosbuvir;
(2S)-isopropyl 2-(((((2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate; Sofosbuvir;
S)-N-hydroxy-4-(3-methyl-2-phenylbutanamido)benzamide
S)-N-hydroxy-4-(3-methyl-2-phenylbutanamido)benzamide
4-[[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-2-methoxy-benzoic acid; Alisertib
4-[[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-2-methoxy-benzoic acid; Alisertib
4-[[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-2-methoxy-benzoic acid; Alisertib
4-[[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-d][2]benzazepin-2-yl]amino]-2-methoxy-benzoic acid; Alisertib
5-[[2-[(3R)-3-Aminopiperidin-1-yl]biphenyl-3-yl]methylidene]-1,3-thiazolidine-2,4-dione
5-[[2-[(3R)-3-Aminopiperidin-1-yl]biphenyl-3-yl]methylidene]-1,3-thiazolidine-2,4-dione
alpha-[[(2R)-2-[(1S)-1-Hydroxy-2-(hydroxyamino)-2-oxoethyl]-4-methyl-1-oxopentyl]amino]benzeneacetic acid cyclopentyl ester; Tosedostat
alpha-[[(2R)-2-[(1S)-1-Hydroxy-2-(hydroxyamino)-2-oxoethyl]-4-methyl-1-oxopentyl]amino]benzeneacetic acid cyclopentyl ester; Tosedostat
22,23-Dihydroavermectin B1
22,23-Dihydroavermectin B1
CV 104; Covitol 1210; NSC 173849; d-α-Tocopherol Acid Succinate; α-Vitamin E Succinate; Vitamin E d-α-Tocosuccinate
CV 104; Covitol 1210; NSC 173849; d-α-Tocopherol Acid Succinate; α-Vitamin E Succinate; Vitamin E d-α-Tocosuccinate
1-Methyl-N-[2-methyl-4-[2-(2-methylphenyl)diazenyl]phenyl-1H-pyrazole-5-carboxamide
1-Methyl-N-[2-methyl-4-[2-(2-methylphenyl)diazenyl]phenyl-1H-pyrazole-5-carboxamide
(2R,
(2R,

-1-oxopropan-2-yl)amino)-1-oxopropan-2-yl)-2-methylthiazole-5-carboxamide; ONX-0912; PR-047
N-((S)-3-methoxy-1-(((S)-3-methoxy-1-(((S)-1-((R)-2-methyloxiran-2-yl)-1-oxo-3-phenylpropan-2-yl)amino)-1-oxopropan-2-yl)amino)-1-oxopropan-2-yl)-2-methylthiazole-5-carboxamide; ONX-0912; PR-047
5-Fluoro-2’-deoxycytidine; FCDR; FdCyd; NSC-48006
5-Fluoro-2’-deoxycytidine; FCDR; FdCyd; NSC-48006
(6R,7R)-3-[2-(2,4-dinitrophenyl)ethenyl]-8-oxo-7-[(2-thiophen-2-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
(6R,7R)-3-[2-(2,4-dinitrophenyl)ethenyl]-8-oxo-7-[(2-thiophen-2-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Andrographolide
Andrographolide
N-Acetyl-D-erythro-sphingosine
N-Acetyl-D-erythro-sphingosine
N-Acetyl-D-erythro-sphinganine; Dihydroceramide-C2
N-Acetyl-D-erythro-sphinganine; Dihydroceramide-C2
N-[4-(4-Morpholinyl)butyl]-2-benzofurancarboxamide; CL-82198
N-[4-(4-Morpholinyl)butyl]-2-benzofurancarboxamide; CL-82198
6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)-butoxy]-3,4-dihydro-2(1H)-quinolinone
6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)-butoxy]-3,4-dihydro-2(1H)-quinolinone
(6R,7R)-3-[(3-carboxy-4-nitrophenyl)sulfanylmethyl]-8-oxo-7-[(2-thiophen-2-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
(6R,7R)-3-[(3-carboxy-4-nitrophenyl)sulfanylmethyl]-8-oxo-7-[(2-thiophen-2-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid

 



產(chǎn)品對(duì)比 二維碼 在線交流

掃一掃訪問(wèn)手機(jī)商鋪

對(duì)比框

在線留言
都江堰市| 三穗县| 贵溪市| 巴彦县| 礼泉县| 建瓯市| 宾川县| 麦盖提县| 祁东县| 鲁甸县| 大名县| 五莲县| 广州市| 金阳县| 乐昌市| 兖州市| 石首市| 闵行区| 灌云县| 河西区| 南皮县| 石河子市| 南郑县| 宕昌县| 淮滨县| 汪清县| 瓮安县| 高碑店市| 眉山市| 准格尔旗| 崇左市| 盐山县| 东方市| 罗城| 迁西县| 胶南市| 六枝特区| 万山特区| 麟游县| 丹棱县| 全州县|